Sunday - November 15, 2026
Boehringer Ingelheim: CVMP Adopts a Positive Opinion for SCOVELLA, First Therapy for Hyperinsulinaemia in Horses With Equine Metabolic Syndrome
November 10, 2026
INGELHEIM AM RHEIN, Germany, Nov. 10 (TNSrep)-- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:

* * *

CVMP adopts a positive opinion for SCOVELLA(R), the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome

Ingelheim, Germany 10/11/2026

* SCOVELLA(R) was developed to reduce hyperinsulinaemia in insulin-dysregulated horses, a key underlying driver of laminitis - a common, painful inflamm . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products